Genmab Agrees to Buy Cancer Drugmaker Merus for $8 Billion

Denmark’s Genmab A/S agreed to acquire Merus NV, a Dutch biotechnology company that’s developing a treatment for cancer of the head and neck, for about $8 billion....

Redirecting to full article...